Bionime Corp

Bionime Corp's capital structure is highly leveraged, with a debt-to-equity ratio of 1.75, indicating significant reliance on debt financing. The company's liquidity position is weak, as evidenced by a current ratio of 0.75 and only TWD 2.18 million in cash and equivalents, which is far below the TWD 3.06 billion in long-term debt. This suggests a high liquidity risk, as the company may struggle to meet short-term obligations without external financing. Profitability metrics are negative, with a return on equity of -10.33% and a return on assets of -3.16%, both well below the industry median for medical equipment and supplies firms. The company reported a net loss of TWD 180.28 million and an operating loss of TWD 206.80 million in the latest period, indicating operational inefficiencies or declining demand. Gross profit of TWD 627.81 million suggests some margin preservation, but insufficient to offset operating costs. The company's revenue is concentrated in overseas markets, with no disclosed breakdown of regional contributions. However, the absence of a domestic revenue segment and the reliance on international distribution channels may expose the company to currency fluctuations and geopolitical risks, particularly in the Americas and Europe. No specific segment disclosures are available in the input data. Growth trajectory appears negative, with no revenue growth data provided in the input. The company's operating cash flow of TWD 494.80 million is a positive sign, but it is offset by a free cash flow of -TWD 285.44 million due to capital expenditures of -TWD 288.39 million. This suggests that the company is investing in expansion or maintenance, but the returns are not yet materializing in the bottom line. Risk factors include a high debt load and weak liquidity, with net cash negative after subtracting total debt. The company's dilution risk is currently low, as shares outstanding remain unchanged between basic and diluted counts. However, the need for additional financing could lead to future dilution, particularly if the company's operating losses persist. Recent events include the latest financial filing, which shows a continuation of operating losses and high leverage. No recent earnings call transcripts or material regulatory filings are included in the input data, so no additional qualitative insights are available.